Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01813877 · ClinicalTrials.gov registry record · NA

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

A NA study, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
37
Enrollment target

NCT01813877 is a NA study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 37 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01813877, a NA study, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target

Study Summary

It was previously shown that 18F-DOPA PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of 18F-DOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.

Interventions

  • RADIATION FDOPA PET/CT

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2012-08-22
Est. Completion 2020-01-14
Phase NA

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

What the Registry Record Tells You About NCT01813877

The ClinicalTrials.gov registry entry for NCT01813877 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which FDOPA PET/CT is the first listed.

NCT01813877 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01813877 about?

NCT01813877 is a clinical study titled "Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma". It was previously shown that 18F-DOPA PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the...

What is the current status of trial NCT01813877?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2012-08-22. Estimated completion is 2020-01-14.

What interventions are being tested in trial NCT01813877?

The interventions under investigation include: FDOPA PET/CT (RADIATION).

Who is sponsoring clinical trial NCT01813877?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.